Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecartus
brexucabtagene autoleucel · Kite Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
LAMPGEN ANALYSIS
Why it matters
The decision expands a CD19 CAR T product into adult B-ALL.
What research teams should watch
Verify lineage and relapse status and plan bridging treatment and infusion timing around manufacturing.
PRIMARY RECORDS